PCVX - Vaxcyte, Inc.
Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have assigned a buy recommendation to the company.
The average of price targets set by Wall Street analysts indicates a potential upside of 75.6% in Vaxcyte (PCVX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
What happened Vaxcyte, Inc. (NASDAQ: PCVX) closed a financing on October 9, 2026, and sold $575 million of 1.50% convertible senior notes due 2032. The notes are senior unsecured obligations. The initial conversion rate is 11.1607 shares per $1,000 principal amount, or about $89.60 a share. The company also sold 7,412,500 shares of common stock
Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) EVP Jim Wassil sold 18,000 shares of the company's stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $86.74, for a total transaction of $1,561,320.00. Following the completion of the transaction, the executive vice president owned 145,435 shares in the
SAN CARLOS, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of concurrent underwritten public offerings of 7,412,500 shares of common stock, pre-funded warrants to purchase 400,000 shares of common stock and $500 million aggregate principal amount of 1.50% convertible senior notes due 2032 (the “notes”). The shares of common stock are being sold at a public offering price of $64.00 per share, and the pre-funded warrants are being sold at a public offering price of $63.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The shares of common stock, pre-funded warrants and notes to be sold in the offerings are being offered by Vaxcyte. Vaxcyte has granted the underwriters of the common stock and pre-funded warrant offering a 30-day option to purchase up to an additional 1,171,875 shares of its common stock at the public offering price per share, and has granted the underwriters of the note offering a 30-day option to purchase up to an additional $75 million aggregate principal amount of notes at the public offering price, solely to cover over-allotments, in each case less underwriting discounts and commissions.
Vaxcyte remains a 'Strong Buy' after robust phase 3 OPUS-1 results for VAX-31, demonstrating non-inferiority to Prevnar 20 and Capvaxive in adults. The company offers significant upside with multiple 2027 catalysts: OPUS-2 and OPUS-3 phase 3 data for VAX-31 in adults in the 1st half of 2027 and phase 2 infant data. VAX-31 targets broader pneumococcal strain coverage versus current vaccines, addressing emerging serotypes and aiming for 95% adult IPD coverage.
Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) shares saw unusually-strong trading volume on Tuesday after Needham and Company LLC raised their price target on the stock from $110.00 to $122.00. Needham and Company LLC currently has a buy rating on the stock. 1,142,393 shares changed hands during mid-day trading, a decline of 21% from the
Vaxcyte (NASDAQ: PCVX) said its investigational 31-valent pneumococcal conjugate vaccine, VAX-31, met all pre-specified primary immunogenicity endpoints in the pivotal Phase III OPUS-1 trial in adults. The randomized, double-blind, active-controlled study enrolled 4,047 U.S. adults, including 3,572 participants aged 50 and older and 475 participants aged 18 to 49. VAX-31 is being developed to prevent invasive
Vaxcyte NASDAQ: PCVX said its investigational 31-valent pneumococcal conjugate vaccine, VAX-31, met all pre-specified primary immunogenicity endpoints in the pivotal Phase III OPUS-1 trial in adults.
SAN CARLOS, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced underwritten public offerings of $500 million of its common stock and pre-funded warrants and $500 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) in separate public offerings registered under the Securities Act of 1933, as amended. All shares of common stock, pre-funded warrants and notes to be sold in the offerings will be offered by Vaxcyte. Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional $75 million of shares of its common stock, and expects to grant the underwriters a 30-day option to purchase up to an additional $75 million aggregate principal amount of notes solely to cover over-allotments. The completion of the common stock and pre-funded warrant offering will not be contingent on the completion of the note offering, and the completion of the note offering will not be contingent on the completion of the common stock and pre-funded warrant offering. The offerings are subject to market and other conditions, and there can be no assurance as to whether or when either offering may be completed, or as to the actual size or terms of either offering.
Vaxcyte, Inc. (PCVX) Discusses Top Line Results From OPUS-1 Phase 3 Trial of VAX-31 Pneumococcal Vaccine Candidate Transcript
Vaxcyte (NASDAQ:PCVX) shares surged 57% in morning trading on Monday after the biotechnology company said its experimental pneumococcal vaccine VAX-31 generated immune responses comparable to rival vaccines in a late-stage study. The results strengthened expectations that VAX-31 could compete with Pfizer's Prevnar 20 and Merck's Capvaxive in the adult pneumococcal vaccine market, which Jefferies estimates could reach $3 billion to $6 billion or more.
Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) saw unusually large options trading activity on Monday. Investors bought 2,615 call options on the stock. This represents an increase of approximately 17% compared to the average volume of 2,238 call options. Key Vaxcyte News Here are the key news stories impacting Vaxcyte this week: Positive Sentiment: VAX-31
Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, Jefferies says.
Shares of Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) reached a new 52-week high on Monday. The company traded as high as $89.00 and last traded at $87.1950, with a volume of 1927060 shares trading hands. The stock had previously closed at $56.48. Vaxcyte News Summary Here are the key news stories impacting Vaxcyte this
Vaxcyte Inc. (NASDAQ:PCVX) stock is surging on Monday on positive topline results from its pivotal Phase 3 OPUS-1 trial evaluating VAX-31, an investigational 31-valent pneumococcal conjugate vaccine.
VAX-31 Met All Prespecified Primary Endpoints Across Age Groups Studied Compared to Prevnar 20® (PCV20) and/or Capvaxive® (PCV21)
SAN CARLOS, Calif., Oct. 04, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced it will host a webcast and conference call tomorrow, October 5, 2026 at 8:00 a.m. ET / 5:00 a.m. PT to present topline data from the OPUS-1 adult pivotal Phase 3 trial evaluating the safety, tolerability and immunogenicity of VAX-31, the Company's 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD) and pneumococcal pneumonia.
KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.
California State Teachers Retirement System boosted its position in Vaxcyte, Inc. (NASDAQ: PCVX) by 5,915.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,186,622 shares of the company's stock after buying an additional 8,050,522 shares during the quarter. California State Teachers